Home

Addex Therapeutics Ltd - American Depositary Shares (ADXN)

7.5500
+0.2500 (3.42%)

Addex Therapeutics Ltd is a biopharmaceutical company focused on developing innovative treatments for neurological and psychiatric disorders

The company leverages its expertise in allosteric modulation to identify and develop novel therapies aimed at a variety of conditions, including addiction, anxiety, and epilepsy. By utilizing its proprietary technology platform, Addex works to create safer and more effective therapeutic options that can enhance patient outcomes and address unmet medical needs in the complex field of brain health.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close7.300
Open7.500
Bid7.300
Ask8.170
Day's Range7.300 - 8.000
52 Week Range6.670 - 27.90
Volume31,634
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume9,308

News & Press Releases

Earnings Scheduled For November 22, 2024benzinga.com
Via Benzinga · November 22, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · October 22, 2024
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · October 22, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · September 30, 2024
S&P 500 Edges Higher; American Woodmark Shares Slidebenzinga.com
Via Benzinga · August 27, 2024
Crude Oil Dips; Addex Therapeutics Shares Spike Higherbenzinga.com
Via Benzinga · August 27, 2024
US Stocks Mixed; ScanSource Reports Weak Q4 Resultsbenzinga.com
Via Benzinga · August 27, 2024
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorderbenzinga.com
Addex Therapeutics stock surged after announcing clinical candidate selection with Indivior for substance use disorder treatment. Addex could receive up to $330 million plus royalties under the agreement, while advancing its own GABAB PAM program for chronic cough.
Via Benzinga · August 27, 2024
Why Trip.com Group Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · August 27, 2024
After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidatebenzinga.com
Addex Therapeutics announces Janssen Pharmaceuticals, a Johnson & Johnson unit, has halted ADX71149 development for epilepsy after Phase 2 data.
Via Benzinga · July 22, 2024
ADXN Stock Earnings: Addex Therapeutics Reported Results for Q1 2024investorplace.com
Addex Therapeutics just reported results for the first quarter of 2024.
Via InvestorPlace · June 6, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · May 6, 2024
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Mondayinvestorplace.com
It's time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Monday morning!
Via InvestorPlace · May 6, 2024
Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com
Via Benzinga · April 30, 2024
Why GeneDx Shares Are Trading Higher By 37%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · April 30, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · April 30, 2024
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesdayinvestorplace.com
Our coverage for Tuesday starts with a dive into the biggest pre-market stock movers traders will want to keep an eye on today!
Via InvestorPlace · April 30, 2024
S&P 500 Edges Higher; ON Semiconductor Earnings Top Viewsbenzinga.com
Via Benzinga · April 29, 2024
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Sessionbenzinga.com
Via Benzinga · April 29, 2024
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · April 29, 2024
Crude Oil Down Over 1%; Deciphera Pharmaceuticals Shares Spike Higherbenzinga.com
Via Benzinga · April 29, 2024
Johnson & Johnson-Partnered Addex Therapeutics' Epilepsy Candidate Fails Mid-Stage Study, Stock Tanksbenzinga.com
Latest Phase 2 epilepsy study findings on ADX71149 adjunctive therapy for focal onset seizures. Partnered with Janssen, Addex Therapeutics evaluates treatment efficacy in patients with suboptimal response to standard care.
Via Benzinga · April 29, 2024
Dow Surges Over 100 Points; Domino's Pizza Posts Upbeat Earningsbenzinga.com
Via Benzinga · April 29, 2024
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · April 29, 2024
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Mondayinvestorplace.com
Pre-market stock movers are a great way to start the week as we check out all of the biggest news moving shares on Monday!
Via InvestorPlace · April 29, 2024